NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: DRREDDY · data 2026-10-30
Dr. Reddy's Laboratories Ltd.
In plain words
Price: 4.4% below its 52-week high of ₹1,414.9.
Delivery: 51.6% of traded shares were kept for delivery over the last 10 sessions, against 55.8% over the last 60.
Latest results: a net profit of ₹444 cr for the quarter ended Jun 2026 (-68.7% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹32,984 cr |
| Net profit (last 12 months) | ₹2,798 cr |
| Sales growth, 3 years (yearly) | 11.0% |
| Profit growth, 3 years (yearly) | -1.7% |
Latest results in brief (Q1 FY27)
DRREDDY Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹8,099.8 crore, down 5.5% YoY and up 7.3% QoQ.
Net profit was ₹444.3 crore, down 68.7% YoY and up 101.1% QoQ.
Operating margin was 10.6% (25.4% a year ago).
EPS was ₹5.33, down 68.7% YoY and up 101.1% QoQ.
DRREDDY के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹8,099.8 करोड़; पिछले साल की तुलना में 5.5% की गिरावट, पिछली तिमाही की तुलना में 7.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹444.3 करोड़; पिछले साल की तुलना में 68.7% की गिरावट, पिछली तिमाही की तुलना में 101.1% की बढ़त।
ऑपरेटिंग मार्जिन: 10.6% (एक साल पहले 25.4%)।
EPS: ₹5.33; पिछले साल की तुलना में 68.7% की गिरावट, पिछली तिमाही की तुलना में 101.1% की बढ़त।
DRREDDYના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹8,099.8 કરોડ; ગયા વર્ષની સરખામણીએ 5.5% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 7.3% વધારો.
ચોખ્ખો નફો: ₹444.3 કરોડ; ગયા વર્ષની સરખામણીએ 68.7% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 101.1% વધારો.
ઓપરેટિંગ માર્જિન: 10.6% (એક વર્ષ પહેલાં 25.4%).
EPS: ₹5.33; ગયા વર્ષની સરખામણીએ 68.7% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 101.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
40/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 3/30: Delivery 50.0% over the last 20 sessions vs 56.7% in the 40 before (0.88x); shares delivered per day 1.18x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 45 schemes hold it, about ₹5,728 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 62/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results ● Dividend
- 18 Aug 26Insider SAST disclosure: ICICI Prudential Mutual Fund acquired 7,12,884 shares -1.8% next session
- 22 Jul 26Results Q1 FY27 results: profit −68.7% YoY -3.3% next session
- 10 Jul 26Dividend Dividend ₹8 (ex-date) -2.8% next session
- 12 May 26Results Q4 FY26 results: profit −86.1% YoY -1.1% next session
- 21 Jan 26Results Q3 FY26 results: profit −14.4% YoY +4.4% next session
- 24 Oct 25Results Q2 FY26 results: profit +7.3% YoY +0.4% next session
- 23 Jul 25Results Q1 FY26 results: profit +1.8% YoY +2.1% next session
- 10 Jul 25Dividend Dividend ₹8 (ex-date) -1.2% next session
- 9 May 25Results Q4 FY25 results: profit +21.6% YoY +4.1% next session
- 24 Jan 25Results Q3 FY25 results: profit +2.4% YoY -7.1% next session
- 5 Nov 24Results Q2 FY25 results: profit −15.3% YoY +2.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹8,100 cr | ₹444 cr | -68.7% | 10.6% | 5.33 |
| Mar 2026 | ₹7,546 cr | ₹221 cr | -86.1% | 5.1% | 2.65 |
| Dec 2025 | ₹8,753 cr | ₹1,210 cr | -14.4% | 21.6% | 14.53 |
| Sept 2025 | ₹8,828 cr | ₹1,347 cr | +7.3% | 22.8% | 16.18 |
Common questions
What was Dr. Reddy's Laboratories Ltd.'s latest quarterly profit?
Dr. Reddy's Laboratories Ltd. reported a net profit of ₹444 cr for the quarter ended Jun 2026 (-68.7% on the same quarter a year earlier), on revenue of ₹8,100 cr.
Is Dr. Reddy's Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.21.
What is Dr. Reddy's Laboratories Ltd.'s P/E ratio?
About 40.3, based on the last 12 months' earnings and a price of ₹1,352 (data 2026-10-30).
What is the 52-week high and low of Dr. Reddy's Laboratories Ltd.?
The 52-week high is ₹1,414.9 and the 52-week low is ₹1,101.
Mutual funds holding Dr. Reddy's Laboratories Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 45 schemes holding about ₹5,728 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Parag Parikh Flexi Cap Fund | PPFAS Mutual Fund | 1.23% | ₹1,784 cr |
| SBI Nifty 50 ETF | SBI Mutual Fund | 0.72% | ₹1,462 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 5.45% | ₹500 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 0.96% | ₹492 cr |
| NIPPON INDIA ETF NIFTY 50 BEES | Nippon India Mutual Fund | 0.72% | ₹469 cr |
| Mirae Asset Large Cap Fund | Mirae Asset Mutual Fund | 0.62% | ₹221 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 4.84% | ₹169 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 7.62% | ₹132 cr |
| SBI Nifty Index Fund | SBI Mutual Fund | 0.72% | ₹95 cr |
| Parag Parikh ELSS Tax Saver Fund | PPFAS Mutual Fund | 1.39% | ₹75 cr |
| Nippon India Flexi Cap Fund | Nippon India Mutual Fund | 0.74% | ₹68 cr |
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 0.63% | ₹58 cr |
| Mirae Asset Nifty 50 ETF | Mirae Asset Mutual Fund | 0.72% | ₹38 cr |
| NIPPON INDIA INDEX FUND - NIFTY 50 PLAN | Nippon India Mutual Fund | 0.72% | ₹25 cr |
| ADITYA BIRLA SUN LIFE NIFTY 50 ETF | Aditya Birla Sun Life Mutual Fund | 0.72% | ₹23 cr |
Similar companies
Torrent Pharmaceuticals Ltd (TORNTPHARM) · Laurus Labs Ltd. (LAURUSLABS) · Zydus Lifesciences Limited (ZYDUSLIFE) · Mankind Pharma Ltd. (MANKIND) · Glenmark Pharmaceuticals Limited (GLENMARK)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DRREDDY in NSE Scanner →